Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

• Status: Not yet recruiting
• Trial end date: 2024-03-01

Summary

This is a prospective, open label, parallel controlled study to evaluate the efficacy and safety of neoadjuvant pyrotinib in HER2+ breast cancer patients

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Hebei Medical University Fourth Hospital
• Treatments: Cyclophosphamide; Epirubicin; Taxane; Trastuzumab